PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
17.97%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
18.43%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
58.16%
EPS growth above 1.5x TRVN's 6.04%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
58.16%
Diluted EPS growth above 1.5x TRVN's 6.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
96.23%
Share count expansion well above TRVN's 15.53%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
96.23%
Diluted share count expanding well above TRVN's 15.53%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.94%
OCF growth above 1.5x TRVN's 14.43%. David Dodd would confirm a clear edge in underlying cash generation.
22.94%
FCF growth above 1.5x TRVN's 14.43%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-567.72%
Negative 10Y OCF/share CAGR while TRVN stands at 84.65%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.81%
5Y OCF/share CAGR 1.25-1.5x TRVN's 80.95%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
89.23%
3Y OCF/share CAGR similar to TRVN's 84.74%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-636.46%
Negative 10Y net income/share CAGR while TRVN is at 83.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
93.35%
5Y net income/share CAGR 1.25-1.5x TRVN's 80.19%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
88.82%
3Y net income/share CAGR similar to TRVN's 84.03%. Walter Schloss would attribute it to shared growth factors or demand patterns.
2271.09%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-76.58%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-2.44%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Asset growth above 1.5x TRVN's 69.84%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
756.79%
BV/share growth above 1.5x TRVN's 66.31%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-16.19%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-15.49%
Our R&D shrinks while TRVN invests at 35.01%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-24.67%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.